Efficacy News and Research

RSS
TAXUS Element Stent has comparable levels of TLR and late loss in diabetic and non-diabetic patients

TAXUS Element Stent has comparable levels of TLR and late loss in diabetic and non-diabetic patients

U.S. joins whistleblower suit against Pfizer for drug marketing

U.S. joins whistleblower suit against Pfizer for drug marketing

Weight-based taribavirin reduces anemia, increases sustained virologic response

Weight-based taribavirin reduces anemia, increases sustained virologic response

Boston announces TAXUS ATLAS clinical trial data for complex lesions

Boston announces TAXUS ATLAS clinical trial data for complex lesions

Abbott's Humira gains first-line biologic use for psoriasis treatment: Report

Abbott's Humira gains first-line biologic use for psoriasis treatment: Report

Santaris Pharma paves way to conduct clinical trial of miravirsen in patients with HVC

Santaris Pharma paves way to conduct clinical trial of miravirsen in patients with HVC

AMS reports 12-month study results of Elevate Apical and Posterior Prolapse Repair System

AMS reports 12-month study results of Elevate Apical and Posterior Prolapse Repair System

Results of custirsen Phase 2 trial for advanced prostate cancer published in Journal of Clinical Oncology

Results of custirsen Phase 2 trial for advanced prostate cancer published in Journal of Clinical Oncology

Phase I/II DIGNITY trial abstract of ThermoDox accepted for poster session at 2010 Breast Cancer Symposium

Phase I/II DIGNITY trial abstract of ThermoDox accepted for poster session at 2010 Breast Cancer Symposium

St. Jude Medical announces positive subset data results for Angio-Seal Evolution Vascular Closure Device Registry

St. Jude Medical announces positive subset data results for Angio-Seal Evolution Vascular Closure Device Registry

First in-human study of robotically assisted percutaneous coronary intervention system presented at 22nd TCT

First in-human study of robotically assisted percutaneous coronary intervention system presented at 22nd TCT

NIDA's Avant-Garde Awards support novel approaches for treating tobacco and cocaine addiction

NIDA's Avant-Garde Awards support novel approaches for treating tobacco and cocaine addiction

Boston Scientific reports positive data from PLATINUM Element Stent quantitative coronary angiography study

Boston Scientific reports positive data from PLATINUM Element Stent quantitative coronary angiography study

Aeras and Crucell commence Phase II study of TB vaccine candidate in infants

Aeras and Crucell commence Phase II study of TB vaccine candidate in infants

Novartis' SOM230 reduces cortisol levels in Cushing's disease patients

Novartis' SOM230 reduces cortisol levels in Cushing's disease patients

QR Pharma and MUSC receive $220,000 SBIR grant to study Posiphen in AD transgenic mice

QR Pharma and MUSC receive $220,000 SBIR grant to study Posiphen in AD transgenic mice

FDA grants orphan-drug designation to Catalyst's CPP-115 investigational drug

FDA grants orphan-drug designation to Catalyst's CPP-115 investigational drug

Brown grants exclusive intellectual property license to Tivorsan Pharmaceuticals

Brown grants exclusive intellectual property license to Tivorsan Pharmaceuticals

Biodegradable polymers represent future of stent design

Biodegradable polymers represent future of stent design

Aethlon Medical reestablishes efforts to advance Aethlon Hemopurifier

Aethlon Medical reestablishes efforts to advance Aethlon Hemopurifier

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.